Effect of CD44 deficiency on in vitro and in vivo osteoclast formation
- 2 December 2004
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 94 (5) , 954-966
- https://doi.org/10.1002/jcb.20326
Abstract
In vitro studies have shown that CD44 is involved in the fusion process of osteoclast precursor cells. Yet, in vivo studies do not support this, since an osteopetrotic phenotype has not been described for CD44 knock-out (CD44 k.o.) mice. This discrepancy may suggest that the role of CD44 in fusion may depend on the microenvironment of osteoclast formation. We investigated osteoclast formation of CD44 k.o. and wild-type mice under three conditions: in vitro, both on plastic and on bone and in vivo by analyzing osteoclast number, and size in long bones from wild-type and CD44 k.o. mice. Bone marrow cells from wild-type and CD44 k.o. mice were analyzed for their capacity to form osteoclasts on plastic and on bone in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of NF-kB ligand (RANKL). On plastic, the number of multinucleated tartrate resistant acid phosphatase (TRAP) positive cells in CD44 k.o. cultures was twofold higher than in wild-type cultures. On bone, however, equal numbers of osteoclasts were formed. Interestingly, the total number of osteoclasts formed on bone proved to be higher than on plastic for both genotypes, strongly suggesting that osteoclastogenesis was stimulated by the bone surface, and that CD44 is not required for osteoclast formation on bone. Functional analyses showed that bone resorption was similar for both genotypes. We further studied the osteoclastogenic potential of wild-type bone marrow cells in the presence of CD44 blocking antibodies. Osteoclastogenesis was not affected by these antibodies, a further indication that CD44 is not required for the formation of multinucleated cells. Finally, we analyzed the in vivo formation of osteoclasts by analyzing long bones from wild-type and CD44 k.o. mice. Morphometric analysis revealed no difference in osteoclast number, nor in number of nuclei per osteoclasts or in osteoclast size. Our in vitro experiments on plastic showed an enhanced formation of osteoclasts in the absence of CD44, thus suggesting that CD44 has an inhibitory effect on osteoclastogenesis. However, when osteoclasts were generated on bone, no differences in number of multinucleated cells nor in bone resorption were seen. These observations are in agreement with in vivo osteoclast characteristics, where no differences between wild-type and CD44 k.o. bones were encountered. Therefore, the modulating role of CD44 in osteoclast formation appears to depend on the microenvironment. J. Cell. Biochem. 94: 954–966, 2005.Keywords
This publication has 31 references indexed in Scilit:
- Osteopontin modulates CD44‐dependent chemotaxis of peritoneal macrophages through G‐protein‐coupled receptors: Evidence of a role for an intracellular form of osteopontinJournal of Cellular Physiology, 2003
- Osteopontin Deficiency Produces Osteoclast Dysfunction Due to Reduced CD44 Surface ExpressionMolecular Biology of the Cell, 2003
- Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte developmentPublished by Wiley ,1999
- CD44 Occupancy Prevents Macrophage MultinucleationThe Journal of cell biology, 1998
- Mice Lacking Osteopontin Show Normal Development and Bone Structure but Display Altered Osteoclast Formation In VitroJournal of Bone and Mineral Research, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- CD44 Antibodies Inhibit Osteoclast FormationJournal of Bone and Mineral Research, 1997
- Immunolocalization of CD44 and the ERM family in bone cells of mouse tibiaeJournal of Bone and Mineral Research, 1996
- Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts.The Journal of Experimental Medicine, 1993
- Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody.The Journal of Experimental Medicine, 1992